Lori Macomber - 15 Oct 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, CFO & Treasurer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Lori Macomber
Issuer symbol
KPTI
Transactions as of
15 Oct 2025
Net transactions value
$0
Form type
4
Filing time
16 Oct 2025, 16:25:00 UTC
Previous filing
03 Feb 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Macomber Lori EVP, CFO & Treasurer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith as Attorney-in-Fact for Lori Macomber 16 Oct 2025 0001968671

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +43,650 +409% $0.000000 54,316 15 Oct 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.
F2 Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.